Viracta Therapeutics Inc’s recent filing unveils that its CFO and COO Chevallard Daniel R. unloaded Company’s shares for reported $2493.0 on Feb 27 ’24. In the deal valued at $0.73 per share,3,405 shares were sold. As a result of this transaction, Chevallard Daniel R. now holds 102,306 shares worth roughly $22507.32.
Then, Rothera Mark bought 52,094 shares, generating $25,734 in total proceeds. Upon buying the shares at $0.49, the President and CEO now owns 52,094 shares.
Before that, Rothera Mark bought 47,906 shares. Viracta Therapeutics Inc shares valued at $23,627 were divested by the President and CEO at a price of $0.49 per share. As a result of the transaction, Rothera Mark now holds 100,000 shares, worth roughly $22000.0.
Leerink Partners downgraded its Viracta Therapeutics Inc [VIRX] rating to a Market perform from a an Outperform in a research note published on August 16, 2024; the price target was decreased to $3 from $5. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who began to cover the stock in early February with a ‘”an Outperform”‘ rating. H.C. Wainwright began covering VIRX with “Buy” recommendation on May 03, 2021. SVB Leerink started covering the stock on April 26, 2021. It rated VIRX as “an Outperform”.
Price Performance Review of VIRX
On Tuesday, Viracta Therapeutics Inc [NASDAQ:VIRX] saw its stock fall -5.03% to $0.22. Over the last five days, the stock has lost -6.56%. Viracta Therapeutics Inc shares have fallen nearly -61.26% since the year began. Nevertheless, the stocks have fallen -66.77% over the past one year. While a 52-week high of $1.31 was reached on 04/12/24, a 52-week low of $0.20 was recorded on 10/29/24. SMA at 50 days reached $0.2358, while 200 days put it at $0.5861.
Levels Of Support And Resistance For VIRX Stock
The 24-hour chart illustrates a support level at 0.2045, which if violated will result in even more drops to 0.1883. On the upside, there is a resistance level at 0.2325. A further resistance level may holdings at 0.2443. The Relative Strength Index (RSI) on the 14-day chart is 41.93, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0069, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 78.60%. Stochastics %K at 34.10% indicates the stock is a holding.
How much short interest is there in Viracta Therapeutics Inc?
A steep rise in short interest was recorded in Viracta Therapeutics Inc stocks on 2024-10-15, dropping by -0.21 million shares to a total of 1.1 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-13 was 1.31 million shares. There was a decline of -18.72%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 25, 2021 when Evercore ISI began covering the stock and recommended ‘”an Outperform”‘ rating along with a $45 price target.
